Swedish Orphan Biovitrum Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Guido Oelkers

Chief Executive Officer (CEO)

kr48.9m

Compensación total

Porcentaje del salario del CEO	25.1%
Permanencia del CEO	7yrs
Participación del CEO	0.1%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Recent updates

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26

Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet

Mar 28

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

Nov 17

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 19

An Intrinsic Calculation For Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Suggests It's 50% Undervalued

Aug 12

Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has A Meaningful Debt Burden

Jun 04

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Guido Oelkers en comparación con los beneficios de Swedish Orphan Biovitrum?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	kr2b
Dec 31 2023	kr49m	kr12m	kr2b
Sep 30 2023	n/a	n/a	kr3b
Jun 30 2023	n/a	n/a	kr3b
Mar 31 2023	n/a	n/a	kr3b
Dec 31 2022	kr47m	kr11m	kr3b
Sep 30 2022	n/a	n/a	kr2b
Jun 30 2022	n/a	n/a	kr3b
Mar 31 2022	n/a	n/a	kr3b
Dec 31 2021	kr42m	kr10m	kr3b
Sep 30 2021	n/a	n/a	kr3b
Jun 30 2021	n/a	n/a	kr3b
Mar 31 2021	n/a	n/a	kr3b
Dec 31 2020	kr33m	kr10m	kr3b
Sep 30 2020	n/a	n/a	kr3b
Jun 30 2020	n/a	n/a	kr3b
Mar 31 2020	n/a	n/a	kr4b
Dec 31 2019	kr33m	kr10m	kr3b
Sep 30 2019	n/a	n/a	kr3b
Jun 30 2019	n/a	n/a	kr3b
Mar 31 2019	n/a	n/a	kr3b
Dec 31 2018	kr26m	kr9m	kr2b
Sep 30 2018	n/a	n/a	kr2b
Jun 30 2018	n/a	n/a	kr2b
Mar 31 2018	n/a	n/a	kr1b
Dec 31 2017	kr16m	kr5m	kr1b

Compensación vs. Mercado: La compensación total de Guido($USD4.49M) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD2.33M).

Compensación vs. Ingresos: La compensación de Guido ha sido consistente con los resultados de la empresa en el último año.

CEO

Guido Oelkers (58 yo)

7yrs

Permanencia

kr48,883,000

Compensación

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Guido Oelkers	CEO & President	7yrs	kr48.88m	0.11% SEK 105.7m
Henrik Stenqvist	Chief Financial Officer	5.8yrs	sin datos	0.015% SEK 14.0m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.3yrs	sin datos	0.0079% SEK 7.6m
Daniel Rankin	Head of Strategy & Corporate Development	2.3yrs	sin datos	0.0058% SEK 5.6m
Lena Bjurner	Head of Human Resources	1.3yrs	sin datos	sin datos
Armin Reininger	Senior Scientific & Medical Advisor	7.3yrs	sin datos	0.0047% SEK 4.5m
Norbert Oppitz	Head of International	6.6yrs	sin datos	0.010% SEK 9.9m
Sofiane Fahmy	Head of Europe	5.3yrs	sin datos	0.0078% SEK 7.5m
Duane Barnes	Head of North America	3.3yrs	sin datos	sin datos
Mahmood Ladha	Head of Strategic Transformation Operations	no data	sin datos	0.0018% SEK 1.8m
Christine Wesstrom	Head of Technical Operations	2.2yrs	sin datos	0.0030% SEK 2.9m
Lydia Abad-Franch	Senior VP	1.3yrs	sin datos	sin datos

5.3yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SOBI es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hans Wigzell	Chairman of Scientific Advisory Board	23.3yrs	kr158.00k	sin datos
Helena Saxon	Director	13.1yrs	kr828.00k	0.0059% SEK 5.7m
Anders Ullman	Director	less than a year	kr463.00k	0.00088% SEK 848.2k
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ralf Pettersson	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stefan Del Prato	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	sin datos	sin datos
Annette Clancy	Independent Chairman	10yrs	kr770.00k	0.0010% SEK 963.9k
Staffan Schuberg	Independent Director	4yrs	kr827.00k	0.0019% SEK 1.8m
Filippa Stenberg	Director	3yrs	kr673.00k	0.00015% SEK 144.6k
Katy Mazibuko	Employee Representative Director	1.3yrs	sin datos	sin datos
Christophe Bourdon	Independent Director	less than a year	kr433.00k	sin datos

3.5yrs

Permanencia media

53.5yo

Promedio de edad

Junta con experiencia: La junta directiva de SOBI se considera experimentada (3.4 años de antigüedad promedio).

Swedish Orphan Biovitrum Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Recent updates

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Independent Director recently bought kr439k worth of stock

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa

Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi

Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet

Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study

Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH)

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022